NTLA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -687.61% compared to Intellia Therapeutics's net margin of --. Intellia Therapeutics's return on equity of -56.9% beat Perspective Therapeutics's return on equity of --.

Intellia Therapeutics has a consensus price target of $37.11, signalling upside risk potential of 213.7%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 241.58%. Given that Perspective Therapeutics has higher upside potential than Intellia Therapeutics, analysts believe Perspective Therapeutics is more attractive than Intellia Therapeutics.

Intellia Therapeutics has a beta of 2.211, which suggesting that the stock is 121.143% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are larger than Perspective Therapeutics quarterly revenues of --. Intellia Therapeutics's net income of -$114.3M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 26.18x versus 29.11x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 12.06%. Intellia Therapeutics's return on equity of -56.9% beat Electromed's return on equity of 16.57%.

Intellia Therapeutics has a consensus price target of $37.11, signalling upside risk potential of 213.7%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 79.63%. Given that Intellia Therapeutics has higher upside potential than Electromed, analysts believe Intellia Therapeutics is more attractive than Electromed.

Intellia Therapeutics has a beta of 2.211, which suggesting that the stock is 121.143% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are larger than Electromed quarterly revenues of $15.7M. Intellia Therapeutics's net income of -$114.3M is lower than Electromed's net income of $1.9M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 23.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 26.18x versus 2.72x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 21.68%. Intellia Therapeutics's return on equity of -56.9% beat Eli Lilly and's return on equity of 78.25%.

Intellia Therapeutics has a consensus price target of $37.11, signalling upside risk potential of 213.7%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 25.05%. Given that Intellia Therapeutics has higher upside potential than Eli Lilly and, analysts believe Intellia Therapeutics is more attractive than Eli Lilly and.

Intellia Therapeutics has a beta of 2.211, which suggesting that the stock is 121.143% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Intellia Therapeutics's net income of -$114.3M is lower than Eli Lilly and's net income of $2.8B. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 26.18x versus 14.04x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 26.7%. Intellia Therapeutics's return on equity of -56.9% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Intellia Therapeutics has a consensus price target of $37.11, signalling upside risk potential of 213.7%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.46%. Given that Intellia Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Intellia Therapeutics is more attractive than Regeneron Pharmaceuticals.

Intellia Therapeutics has a beta of 2.211, which suggesting that the stock is 121.143% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Intellia Therapeutics's net income of -$114.3M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 26.18x versus 4.46x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.